Adezkibart is a human-derived monoclonal antibody immunosuppressant that targets the human FMS-like tyrosine kinase 3 ligand (FLT3LG). It was discovered in the Chinese hamster ovary cell line CHO-K1. Adezkibart binds to FLT3LG, blocking the associated signaling pathways to suppress immune responses, thereby exerting an immunosuppressive effect. It holds potential for research in immune-related diseases.